Exabis Library
Welcome to the e-CCO Library!
P427: Impact of curcuma longa on clinical activity and inflammatory markers in patients with active ulcerative colitis: a double-blind randomised placebo-controlled trial 
 2019
ECCO '19 Copenhagen
 Friday, 22 February 2019, 9:41 AM
P427: Neutrophil-to-lymphocyte ration in ulcerative colitis predicts sustained response to infliximab
 2017
 ECCO '17 Barcelona
 Wednesday, 20 February 2019, 10:36 AM
P427: One Year Follow up of Three Phase IB/IIA Clinical Trials of Ex Vivo Expanded Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Fistulizing Crohn's Disease
 2023
 ECCO’23 Copenhagen
 Friday, 14 July 2023, 11:05 AM
P427: The real-life experience of vedolizumab efficacy and safety in Crohn’s disease: a prospective observational multicentre cohort study
 2016
 ECCO '16 Amsterdam
 Friday, 22 February 2019, 9:49 AM
P428 Oral mesalamine use in Crohn’s disease after implementation of the American College of Gastroenterology guidelines: a TARGET-IBD cohort study 
 2020
ECCO'20 Vienna
 Thursday, 30 January 2020, 10:12 AM
P428: A Phase IB/IIA study of remestemcel-L, an allogeneic bone marrow derived mesenchymal stem cell product, for the treatment of medically refractory Crohn’s colitis: A preliminary analysis
 2022
 ECCO'22
 Friday, 11 February 2022, 3:52 PM
P428: Early and Late Fecal Calprotectin Remission - Analysis of a proactive Therapeutic Drug Monitoring Treatment Protocol
 2021
 ECCO'21 Virtual
 Wednesday, 2 June 2021, 4:12 PM
P428: Long-term outcomes of endoscopic ballon dilation for small-bowl strictures using double balloon enteroscopy in patients with Crohn’s disease 
 2019
ECCO '19 Copenhagen
 Friday, 22 February 2019, 9:41 AM
P428: Optimizing thiopurines in Crohn's disease: low dose and low 6-TGN level are effective for maintenance of remission in Asian population
 2017
 ECCO '17 Barcelona
 Wednesday, 20 February 2019, 10:36 AM
P428: Pharmacist led clinic in Inflammatory Bowel Disease
 2023
 ECCO’23 Copenhagen
 Friday, 14 July 2023, 11:05 AM
P428: Pharmacist-led proactive therapeutic drug monitoring with infliximab (PROXIMO): Utility of and cost-saving associated with the use of a rapid assay for assessing drug level
 2018
 ECCO '18 Vienna
 Thursday, 21 February 2019, 9:14 AM
P428: Tofacitinib pharmacokinetics and durability of drug exposure in moderate-to-severe Crohn’s disease patients in Phase 2 induction and maintenance studies
 2016
 ECCO '16 Amsterdam
 Friday, 22 February 2019, 9:49 AM
P429 Clinical utility of thiopurine metabolite monitoring in inflammatory bowel disease and its impact on healthcare utilisation in Singapore 
 2020
ECCO'20 Vienna
 Thursday, 30 January 2020, 10:12 AM
P429: Continued postoperative use of biologics for the prevention of recurrence of Crohn’s disease
 2021
 ECCO'21 Virtual
 Wednesday, 2 June 2021, 4:12 PM
P429: Factors associated with weight gain in patients treated with anti-TNF-α for inflammatory bowel disease: a cohort study 
 2019
ECCO '19 Copenhagen
 Friday, 22 February 2019, 9:41 AM
P429: Mesalazine has no place in the treatment of Crohn's disease. Really?
 2022
 ECCO'22
 Friday, 11 February 2022, 3:52 PM
P429: Mucosal healing after 3 months of conventional IBD treatment: real life data
 2017
 ECCO '17 Barcelona
 Wednesday, 20 February 2019, 10:36 AM
P429: Patient skeletal muscle area and postoperative clinical recurrence in Crohn's disease: a retrospective study
 2023
 ECCO’23 Copenhagen
 Friday, 14 July 2023, 11:05 AM
P429: Robotic-assisted vs. laparoscopic proctectomy for inflammatory bowel disease: Results of the case-match comparison in single institution
 2018
 ECCO '18 Vienna
 Thursday, 21 February 2019, 9:14 AM
P429: The effects of psychiatric treatment in patients with inflammatory bowel disease: a prospective study
 2016
 ECCO '16 Amsterdam
 Friday, 22 February 2019, 9:49 AM